微信直播

AME新书|《胰腺癌》中英文将同步发行,译者招募中

Published at: 2015年第1卷第S1期

关键词:

编者按:胰腺癌作为一种诊断难、治疗难的消化道恶性肿瘤,其发病率和死亡率近年来明显上升。为推广胰腺癌诊治的研究成果,分享国际同行的经验总结,AME 出版社着力打造了一本教科书式、与时俱进、与国际接轨的英文专著:Pancreatic Cancer, 现全力招募译者翻译英文原著,推出《胰腺癌》中文版,届时中英文著作将全球同步发行。在此,我们诚邀国内优秀医学工作者参与本书翻译,成为本书中文版译者,与 Pancreatic Cancer 英文原著第一时间“亲密接触”,将精彩内容带给国内同行!(认领方法以及文章标题见文末)

本书由赵玉沛教授(北京协和医院)、Lei Zheng 教授(Johns Hopkins University School of Medicine)担任主编,副主编包括张太平教授(北京协和医院)、Barish H. Edil, MD (University of Colorado)、Matthew J. Weiss, MD (Johns Hopkins University School of Medicine)、Jin He, MD (The Johns Hopkins Hospital)。邀请了美国和中国为主的百余名专家撰文(见作者分布图),紧跟国际前沿研究动态,旁征博引,以胰腺癌的流行病学、病理学、诊断方法、治疗方案以及预后等角度,从超声内镜在胰腺癌早期诊断中的应用价值、应用前景和挑战,到不可切除胰头癌的疼痛管理,聚焦胰腺癌的诊断和治疗,系统地阐述胰腺癌的研究进展,对临床医生的诊断、治疗具有重要价值。

编风采

赵玉沛,北京协和医院院长,兼任中国医学科学院、北京协和医学院副院长。中国科学院院士,著名外科学教授,博士生导师,享受国务院特殊津贴。我国普通外科的领军人物,国内外公认的著名胰腺外科专家。现任中华医学会副会长,外科学分会主任委员、全国胰腺外科学组组长;北京医师协会副会长;国务院学位委员会学科评议组成员;前任亚洲外科学会主席。

Lei Zheng, MD, PhD, Associate Professor, Departments of Oncology, Surgery; The Sidney Kimmel Cancer Center; The Skip Viragh Center for Pancreatic Cancer Research and Clinical Care; The Sol Goldman Pancreatic Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

领目录

1. Pancreatic cancer incidence and mortality patterns in China, 2011

2. Glucose intolerance and the risk of pancreatic cancer

3. The role of epithelial-mesenchymal transition in pancreatic cancer

4. Histamine regulation of pancreatitis and pancreatic cancer: a review of recent findings  

5. Imaging of pancreatic cancer: an overview

6. Delayed diagnosis of pancreatic cancer reported as more common in a population of North African young adults

7. Pancreatic cancer surgery: past, present, and future

8. Current surgical management of pancreatic cancer

9. Surgical treatment of pancreatic head cancer: concept revolutions and arguments

10. Pancreatic cancer surgery and nutrition management: a review of the current literature

11. Preoperative therapies for resectable and borderline resectable pancreatic cancer

12. Can pancreaticoduodenectomy performed at a comprehensive community cancer center have comparable results as major tertiary center?

13. Outcomes of resected pancreatic cancer in patients age ≥70

14. Laparoscopic pancreaticoduodenectomy: a descriptive and comparative review

15. Surgery for oligometastasis of pancreatic cancer

16. Role of gemcitabine as second-line therapy after progression on FOLFIRINOX in advanced pancreatic cancer: a retrospective analysis

17. Intraperitoneal gemcitabine chemotherapy as an adjuvant treatment for patients with resected pancreatic cancer: phase II and pharmacologic studies

18. Advances of stereotactic body radiotherapy in pancreatic cancer

19. The role of radiotherapy in management of pancreatic cancer

20. Re-irradiation with stereotactic body radiation therapy as a novel treatment option for isolated local recurrence of pancreatic cancer after multimodality therapy: experience from two institutions  

21. Evaluation of normal tissue exposure in patients receiving radiotherapy for pancreatic cancer based on RTOG 0848

22. Self-expanding metal stents (SEMS) provide superior outcomes compared to plastic stents for pancreatic cancer patients undergoing neoadjuvant therapy

23.Nanovector-based therapies in advanced pancreatic cancer

24.Immunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trials

25. Current and future systemic treatment options in metastatic pancreatic cancer  

26. Treatment of locally advanced unresectable pancreatic cancer: a 10-year experience

27. A comparison of three treatment strategies for locally advanced and borderline resectable pancreatic cancer

28. Locally advanced versus metastatic pancreatic cancer: two different diseases with two different treatment approaches?

29. HIFU for palliative treatment of pancreatic cancer

30. Use of irreversible electroporation in unresectable pancreatic cancer

31. Quality-of-life (QoL) as a predictive biomarker in patients with advanced pancreatic cancer (APC) receiving chemotherapy: results from a prospective multicenter phase 2 trial

32. Change in CA 19-9 levels after chemoradiotherapy predicts survival in patients with locally advanced unresectable pancreatic cancer

认领方法

方法一:点击阅读原文登录系统认领(欢迎关注AME科研时间amegroups公众号)。

方法二:点击/复制AME认领系统链接:(推荐)

http://rl.amegroups.com/User/Assignment?Type=0001&HidTaskNO=PC_001

Step 1. 尚未注册账号的认领者需要【注册】并激活账号:点击链接(http://rl.amegroups.com)。

Step 2. 用户登录并进入【翻译】板块,选择【NO.】:如PC_001, 点击认领即可;或查询可认领文章,从【待认领】文章中选择认领。

Step 3. 认领成功后,请选择【下载】来获取原文,同时请务必查看【要求】,按要求翻译文章。有问题请联系下列邮箱:kysj@amepc.org 。每人最多认领两篇。

认领截止日期:本次认领长期有效,直至认领完毕。

认领成功后,请在认领成功后的三周内将翻译稿及个人简介发送到kysj@amepc.org。

凡翻译质量通过审核的译者,可获得:

  1. 每翻译一篇文章,即可获得价值 200 元人民币的科研时间积分(200快币)以及免费登录视频数据库 ASVIDE,观看手术视频(积分限免)。

  2. 译者署名。

  3. 获赠本书中英文版各一本。

看到礼物心动了吗?想提高译稿审核的通过率吗?那就记得一定要按照上述要求来翻译哦!

点击“链接”即可看到以上文章的详细信息及网址链接。

http://rl.amegroups.com/User/Assignment?Type=0001&HidTaskNO=PC_001

本书现正火热预售中,扫描下方二维码即可订购哦~

doi:

10.3978/kysj.2014.1.1305
comments powered by Disqus

附件